Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Essential Hypertension

In brief

Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A(Sacubitril∙Valsartan)

Key facts

Study ID

NCT06643819

Run by

Chong Kun Dang Pharmaceutical

People needed

324

Starts

2024-10-14

Expected to finish

2026-12-31

Last updated by the study team

2025-12-11

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants who are 19 years old or older.
• Participants who have voluntarily decided to participate in this clinical trial and signed ICF.

You may not qualify if…

• Participants with a history of secondary hypertension or suspected secondary hypertension.
• Participants with a orthostatic hypotension.
• Participants who require combination administration of antihypertensive drugs other than clinical trial drugs during the clinical trial participation period.
• Participants with type 1 diabetes or poorly controlled diabetes.
• Participants who treated other clinical trial drugs within 4 weeks of screening visit.
• Participants with a history of drug or alcohol abuse or suspected patient within 24 weeks as of the time of screening
• Pregnant women, lactating women, or Subjects who do not agree to use appropriate contraception during the clinical trial period and for two weeks after the end of administration of the last clinical trial drug
• Participants who are unable to participate in this clinical trial at the discretion of the investigator.

Where it is running

• Wonju Severance Christian Hospital — Wŏnju, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.